China NMPA Product Recall - Fully automated immunoassay analyzer, fully automated biochemical analyzer, fully automated biochemical immunoassay analyzer

Aussendo Medical Devices Trading (China) Co., Ltd. initiated a voluntary Class II recall for several automated medical devices, as announced by the National Medical Products Administration (NMPA) and referenced by the Shanghai Food and Drug Administration (SFDA) on December 5, 2018. The recall specifically targets three product categories: fully automated immunoassay analyzers, fully automated biochemical analyzers, and fully automated biochemical immunoassay analyzers. The core issue prompting this recall is a critical malfunction where the affected products may inaccurately extend the onboard stability time of reagents loaded onto them. This error poses a significant risk as it could lead to the use of expired or degraded reagents, potentially resulting in unreliable or incorrect diagnostic test results, which could compromise patient care. Under the regulatory oversight of the NMPA, Aussendo Medical Devices Trading (China) Co., Ltd. voluntarily undertook this Class II recall to address the defect. This designation signifies a situation where the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The company is required to implement the recall by providing detailed information on affected models, specifications, and batches, as documented in the "Medical Device Recall Event Report Form," ensuring compliance with national medical device regulations and prioritizing patient safety.